PROLIDASE LEVEL IS INCREASED IN CORONARY ARTERY DISEASE AND ISCHEMIC
MITRAL VALVE INSUFFICIENCY
Abstract
Background: Serum prolidase levels change decisively in coronary artery
disease and valvular disease. The aims of this study are to determine
how the serum prolidase level will vary in patients who have undergone
coronary bypass surgery due to mitral insufficiency and those without
ischemic mitral regurgitation and those with ischemic mitral
regurgitation. Methods: A total of 45 patients who were operated with
coronary bypass surgery were selected. Group 1 patients were defined as
patients who had coronary artery bypass surgery and did not have mitral
insufficiency (25 patients), and Group 2 patients were defined as
patients who had undergone coronary artery bypass surgery and had mitral
insufficiency (20 patients). Before and after coronary artery bypass
surgery, blood was taken from the patients and their prolidase levels
were measured. Results: In Group 1 patients, pre- and postoperative
serum prolidase levels were calculated as 1038.2 and 1289.43 U/L,
respectively. In Group 2 patients, pre- and postoperative serum
prolidase levels were calculated as 1084.07 and 1337.74 U/L,
respectively. There is a significant difference between the serum
prolidase (U/L) levels in the blood of group 1 and group 2 patients
entering the operation and the blood after CPB (p<0.05).
Conclusion: Serum prolidase level was found to be high in both patient
groups. Pre- and postoperative serum prolidase levels were higher in
patients with mitral valve insufficiency. Prolidase level is increased
in coronary artery disease and mitral valve insufficiency.